<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01364246</url>
  </required_header>
  <id_info>
    <org_study_id>BKCR-MS-1.0(2010)</org_study_id>
    <nct_id>NCT01364246</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica</brief_title>
  <official_title>Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Beike Bio-Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Nanjing Brain Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing University Medical College Affiliated Wuxi Second Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Beike Bio-Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple sclerosis (MS) has been classically regarded as a chronic inflammatory autoimmune
      demyelinating disease of the central nervous system, along with a considerable pathological
      heterogeneity. Neuromyelitis optica (NMO) is a severe inflammatory, demyelinating disease,
      and its clinical characteristics include recurrent optic neuritis and longitudinally
      extensive transverse myelitis.

      Current therapies provide only modest control of progressive Multiple Sclerosis and
      Neuromyelitis Optica.Stem cell therapy might open a light horizon in approaching to an
      efficient treatment in progressive MS and NMO. In this study, the safety and efficacy of
      Human Umbilical Cord Mesenchymal Stem Cells transplantation will be evaluated in patients
      with progressive MS and NMO.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score of Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>1 year after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Evoked Potential (VEP)</measure>
    <time_frame>1 year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brainstem Auditory Evoked Potential (BAEP)</measure>
    <time_frame>1 year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Somatosensory Evoked Potential(SEP)</measure>
    <time_frame>1 year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Magnetic Resonance Imaging （MRI） Scan</measure>
    <time_frame>1 year after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Progressive Multiple Sclerosis</condition>
  <condition>Neuromyelitis Optica.</condition>
  <arm_group>
    <arm_group_label>Human umbilical cord mesenchymal stem cells transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human umbilical cord mesenchymal stem cells</intervention_name>
    <description>Participants will be given hUC-MSCs transplantation.</description>
    <arm_group_label>Human umbilical cord mesenchymal stem cells transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  McDonald Diagnosis of Multiple Sclerosis or 2006 Diagnosis of neuromyelitis optica.

          -  Aged 16-65 years.

          -  Disease duration≥2years

          -  Poor response to steroid therapy.

          -  Written informed consent and follow the clinic trail procedure

        Exclusion Criteria:

          -  Cardiac insufficiency; Renal insufficiency; hepatic insufficiency; Total bilirubin
             higher than 1.5 times of upper limit of normal value; AST /ALT higher than 2.5 times
             of upper limit of normal value.

          -  Combined Pneumonia or other Severe systemic bacteria infection.

          -  Severe drug allergic history or anaphylaxis to 2 or more food or medicine.

          -  Intracranial hypertension dues to Other brain lesions (eg. Brain cancer)/

          -  HIV+, TPPA +， patients diagnosed as HBV or HCV.

          -  Tumor Markers +

          -  Severe psychotic patients, cognitive dysfunction,Or can not understand or sign the
             Consent Form.

          -  Coagulation disorders.

          -  Uncontrolled hypertension after treatment，blood pressure≥180mmHg/110 mmHg.

          -  Pregnancy.

          -  Enrollment in other trials in the last 3 months.

          -  Other criteria the investigator consider improper for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yun Yun Xu</last_name>
    <email>xuyun20042001@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanjing University Medical College Affiliated Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Xu</last_name>
      <email>xuyun20042001@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2011</study_first_submitted>
  <study_first_submitted_qc>May 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2011</study_first_posted>
  <last_update_submitted>November 26, 2012</last_update_submitted>
  <last_update_submitted_qc>November 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Progressive Multiple Sclerosis</keyword>
  <keyword>neuromyelitis optica</keyword>
  <keyword>Umbilical Cord Mesenchymal Stem Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

